Company intelligence / Profile preview
Gubra
Hørsholm, Denmarkgubra.dk ↗
- Ownership
- Public · GUBRA
- Employees
- ~200
- Development stage
- Phase 1
01
Overview
Gubra has a robust R&D pipeline with both internal and partnered programs. Four projects are in clinical development, including two in Phase I. The company’s lead asset is an amylin analog for weight management that has been partnered with AbbVie in a deal worth up to $2.2 billion. Other programs target metabolic and fibrotic indications using advanced peptide modalities.
- Therapeutic areas
- OtherEndocrinologyImmunologyMetabolic Disorders
- Modalities
- PeptidesPeptide-drug conjugateSmall molecule (as part of preclinical profiling services)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
AbbVie ($2.2B+ deal for amylin analog "GUBamy")Boehringer IngelheimBayerSilence TherapeuticsHemab Therapeutics
04
Financials
- Market cap
- $730.8M
- Total revenue
- $394.1M
- Enterprise value
- $624M
Beyond the preview
Go deeper on Gubra.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Gubra.